Company news

X4 Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

X4 Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Mavorixafor for the Treatment of WHIM Syndrome

December 9, 2020

X4 Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

November 4, 2020

X4 Pharmaceuticals Appoints Art Taveras, Ph.D., as Chief Scientific Officer

November 1, 2020

X4 Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 5, 2020

October 21, 2020

X4 Pharmaceuticals Announces Fast Track Designation Granted by the FDA to Mavorixafor for the Treatment of WHIM Syndrome

October 7, 2020

X4 Pharmaceuticals Expands Board of Directors Through Appointment of Biopharmaceutical Industry Veteran Alison Lawton

September 30, 2020

X4 Pharmaceuticals Announces Publication of Mavorixafor Phase 2 Clinical Data for Treatment of WHIM Syndrome in ‘Blood’ - the Official Journal of the American Society of Hematology

September 1, 2020

X4 Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update

July 29, 2020

X4 Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on July 30, 2020

July 15, 2020

X4 Pharmaceuticals Presents Positive Clinical Data from Phase 2 Study of Mavorixafor in WHIM Syndrome at EHA 2020

June 11, 2020

X4 Pharmaceuticals Promotes Renato Skerlj, Ph.D., to Chief Scientific Officer

June 10, 2020

X4 Pharmaceuticals Announces Data from Phase 2 Open-Label Extension Trial of Mavorixafor in WHIM Syndrome as Published in EHA Abstract

May 13, 2020

X4 Pharmaceuticals Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

May 11, 2020

X4 Pharmaceuticals Provides Corporate Update, Including Expected Impact of COVID-19, and Reports First Quarter 2020 Financial Results

May 6, 2020

X4 Pharmaceuticals to Announce First Quarter 2020 Financial Results and Provide Recent Business Highlights on May 7, 2020

April 22, 2020

X4 Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results

March 11, 2020

X4 Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide Recent Business Highlights on March 12, 2020

February 26, 2020

X4 Pharmaceuticals Granted New Composition of Matter Patent for Late-Stage Clinical Candidate Mavorixafor

February 11, 2020

X4 Pharmaceuticals Initiates Phase 1b Clinical Trial of Mavorixafor in Combination with Ibrutinib for the Treatment of Waldenström’s Macroglobulinemia (WM)

December 29, 2019

X4 Pharmaceuticals Prices $65 Million Public Offering of Common Stock and Class B Warrants

November 25, 2019

X4 Pharmaceuticals Receives Breakthrough Therapy Designation from the FDA for Mavorixafor for the Treatment of WHIM Syndrome

November 11, 2019

X4 Pharmaceuticals Reports Third Quarter 2019 Financial Results and Recent Business Highlights

November 6, 2019

X4 Pharmaceuticals Initiates Phase 1b Clinical Trial of Mavorixafor for the Treatment of Severe Congenital Neutropenia

November 4, 2019

X4 Pharmaceuticals Appoints Derek Meisner, J.D., as General Counsel

November 3, 2019

X4 Pharmaceuticals Reports Positive Data from Phase 2a Trial of Mavorixafor in Combination with Axitinib in Advanced Clear Cell Renal Cell Carcinoma Patients

September 29, 2019

X4 Pharmaceuticals Appoints William E. Aliski to Board of Directors

September 22, 2019

X4 Pharmaceuticals Appoints Renato Skerlj, Ph.D. as Senior Vice President of Research and Development

September 17, 2019

← Newer news releases

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 23 decks. Every deck is listed under its year.